Home    Contact Us    Send to Colleague    Search 

   T H A N K   Y O U      F O R   Y O U R   I N T E R E S T

 

28 Jan 2020
Approved 505(b)(2) available for in-licensing:
CHP is pleased to announce the availability of an approved 505(b)(2) product in the cardiovascular space.  US rights only. Asset has significant intellectual property rights.  This p... View Release

6 Aug 2018
Opportunity to Acquire over 160 ANDA's
Commercial Healthcare Partners announces an opportunity to acquire over 160 ANDAs from a single source.  Interested bidders can acquire one or more of these assets.  Therapeutic... View Release

16 Jun 2017
CHP client signs an agreement to commercialize its 505(b)(2) asset for the treatment of Head and Neck Cancer
PNP Therapeutics: BIRMINGHAM, Ala. - PNP Therapeutics Inc. announced today the Food and Drug Administration has granted orphan drug status to Gedeptin, the Company's lead product cand... View Release

11 May 2017
CHP client signs an agreement to commercialize its 505(b)(2) asset for the treatment of glaucoma.
"CHP client signs an agreement to commercialize its 505(b)(2) asset for the treatment of glaucoma.  The product is currently undergoing FDA review."

5 Jul 2016
arGentis receives U.S Patent for Arthritis Treatment
Memphis, TN—arGentis Pharmaceuticals, LLC announced today the issuance of EU patent No. 2,286,218 for a single nucleotide polymorphism (SNP) associated with resistance to immune tolerance. This... View Release

13 Jan 2016
CHP attended the Biotech Showcase partnering meeting
Commercial Healthcare Partners attended the Biotech Showcase partnering meeting associated with the JP Morgan healthcare conference held in San Francisco.  More than 30 meetings were held with... View Release

25 Oct 2015
CHP collaboration with Finston Consulting
Commercial Healthcare Partners is pleased to announce a collaboration with Finston Consulting based in Washington, D.C.  Finston Consulting will provide data room collection and management ser... View Release

27 Mar 2015
SynAllergy seeks sales representatives and contract sales organizations
SynAllergy seeks sales representatives and contract sales organizations  to call on primary care physicians, pediatricians and other healthcare providers.  Representatives receive a subst... View Release

6 Nov 2014
FDA Advisory Committee Recommends Rockwell Medical's Triferic for Iron Replacement and Maintenance of Hemoglobin in Hemodialysis Patients
WIXOM, Mich., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD)... View Release

12 Aug 2014
Diabetic Retinopathy/Diabetic Macular Edema Compound
Established company with strong IP rights to early stage compound for the treatment of Diabetic Retinopathy/Diabetic Macular Edema wishes to discuss divestiture.  Compound is supported by limi... View Release

11 Apr 2013
Rockwell Medical - SFP
What's happening NOW! Rockwell Medical Soluble Ferric Pyrophosphate (SFP) Phase III asset available from Rockwell Medicaland

24 Apr 2012
Novel therapy for the treatment of Alzheimer’s Disease and Parkinson’s Disease
Commercial Healthcare Partners is pleased to announce the availability of a novel therapy for the treatment of Alzheimer’s Disease and Parkinson’s Disease.  This product is by product of nicot... View Release

4 Dec 2011
Head Lice Product available for in-licensing ex U.S.
Client company has product available for licensing in multiple countries outside the U.S.  Product is not an insecticide and is available in the U.S. through a distribution partner that is wel... View Release

18 Apr 2011
Smoking Cessation
Company holds intellectual property rights to a unique combination of currently marketed products for smoking cessation.  Company is interested in a partner to assist in further development an... View Release

15 Apr 2011
Locking Solution
A Unique locking solution being offered as an alternative to heparin.  This technology is in the early stages of development.  For more information, contact Commercial Healthcare Partners.

5 Mar 2011
Dry Eye Syndrome
Compound with unique transdermal delivery in Phase I development for the treatment of Dry Eye Syndrome.  Company seeks development or licensing opportunity.  Data presented to the America... View Release

2 Mar 2011
Product in Phase IIB
Compound available for licensing and/or development partnership.  This product has been designated an orphan drug by the FDA for the treatment of Scleroderma.  Additional patent is pendin... View Release

You information has been sent.

Thank you for you interest in Commercial Healthcare Partners.  Someone will contact you shortly.

The CHP Team

 

Jan 29 2020
Approved 505(b)(2) available for in-licensing:
CHP is pleased to announce the availability of an approved 505(b)(2) product in the cardiovascular space.  US rights only.  Asset has significant intellectual property rights.  This product is ideally suited for a company with a sales force calling on primary care providers and cardiologists.  Samples and inventory, supply and manufacturing agreements are in place.
Add to Outlook Calendar

Aug 6 2018
OPPORTUNITY TO ACQUIRE 160 ANDAs

Commercial Healthcare Partners announces an opportunity to acquire over 160 ANDAs from a single source

Interested bidders can acquire one or more of these assets. 

Therapeutic areas include CNS, GI, Dermatology, Ophthalmic solution, anti-infectives, women and men’s health.  Please contact CHP with any interest. 

CDA and minimum bid required.

Add to Outlook Calendar

Jun 16 2017
CHP client signs an agreement to commercialize its 505(b)(2) asset for the treatment of Head and Neck Cancer.

PNP Therapeutics:

BIRMINGHAM, Ala. - PNP Therapeutics Inc. announced today the Food and Drug Administration has granted orphan drug status to Gedeptin, the Company's lead product candidate (adenoviral vector expressing E. coli purine nucleoside phosphorylase gene) for the intratumoral treatment of anatomically accessible oral and pharyngeal cancers, including cancers of the lip, tongue, gum, floor of mouth, salivary gland and other oral cavities.

"We are so pleased to have received the orphan drug designation for Gedeptin, which could potentially improve the patient outcomes of currently very difficult to treat diseases," said President of PNP Therapeutics Jim Fuqua. "I am so proud of the outstanding work of the two cofounders..

Add to Outlook Calendar

Jul 26 2016
arGentis receives U.S Patent for Arthritis Treatment
Memphis, TN—arGentis Pharmaceuticals, LLC announced today the issuance of EU patent No. 2,286,218 for a single nucleotide polymorphism (SNP) associated with resistance to immune tolerance. This SNP and will be used as a biomarker to identify patients that will respond to arGentis’ treatment for scleroderma.

For more information, contact:
Tom Davis, President and CEO, arGentis Pharmaceuticals, LLC
901-881-8665
Add to Outlook Calendar

Oct 30 2015
CHP collaboration with Finston Consulting

http://finstonconsulting.com
Commercial Healthcare Partners is pleased to announce a collaboration with Finston Consulting based in Washington, D.C.  Finston Consulting will provide data room collection and management services for CHP clients. 

Finston Consulting is a Micro-Multinational, with services including strategic partnering, business development, trade and tariff advice, public affairs programs & capacity building in the areas of branding, social media, intellectual property (IP), tech transfer, genetic resources, and related environment issues, with special expertise in the BRICs and other emerging markets.
Add to Outlook Calendar

Mar 27 2015
SynAllergy seeks sales representatives and contract sales organizations
SynAllergy seeks sales representatives and contract sales organizations  to call on primary care physicians, pediatricians and other healthcare providers.  Representatives receive a substantial commission and will be trained by SynAllergy. Successful candidates should a background in business to business sales.  synAllergy offers primary care providers the ability to achieve better patient outcomes and a stronger financial future by helping them deliver with great ease, efficiency, and safety skin allergy testing and immunotherapy services.
Add to Outlook Calendar

Nov 6 2014
FDA Advisory Committee Recommends Rockwell Medical's Triferic for Iron Replacement and Maintenance of Hemoglobin in Hemodialysis Patients
WIXOM, Mich., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism today announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food & Drug Administration (FDA) recommended that the Phase 3 Triferic efficacy and safety results support a positive benefit/risk to treat iron loss to maintain hemoglobin in patients with hemodialysis-dependent stage 5 chronic kidney disease (CKD). The ODAC voted in favor of Triferic by a vote of 8 to 3.

A complete dossier is available upon request.  Please contact Commercial Healthcare Partners for more information. Contact information below:

www.commercialhealthcarepartners.com

Phone 615-887-3847.
Jim Usry, Principal
Add to Outlook Calendar

Apr 12 2013
Rockwell - SFP

What's happening NOW!

Rockwell Medical

Rockwell Medical
Soluble Ferric Pyrophosphate (SFP)

Phase III asset available from Rockwell Medical

and
Commercial Healthcare Partners

Add to Outlook Calendar

Apr 18 2012
Biopharm Insight affiliation with CHP
CHP announces its affiliation with a Biopharm Insight, a leading provider of competitive intelligence and market analysis within the healthcare and lifesciences industry.  With access data and analysis within the Biopharm Insight database, CHP has an enhanced capability to serve its client base.  Through its affiliation with BioPharm Insight, CHP can arrange a complimentary demonstration of its capabilities.
Add to Outlook Calendar

Jul 7 2011
arGentis™ announced
arGentis™ announced that it has received a patent in Mexico for its flagship compound ARG201.  ARG201 has been designated as an orphan drug for the treatment of Scleroderma. 
Add to Outlook Calendar

Jul 4 2011
New client relationship with Molecular Design International
Commercial Healthcare Partners (CHP) is pleased to announce that Molecular Design International (MDI) is a client.  CHP will assist MDI in securing a partner for its novel technology to treat Diabetic Retinopathy. 
Add to Outlook Calendar

Jun 29 2011
CHP announces affiliation with Stubbs and Hensel Consulting

Based in Blue Bell, PA Stubbs & Hensel bridges the resource and experience gaps between Pharma/Biotech and Contract Research Organizations.  Jim Usry, Principal of CHP says,  “John Stubbs and Russ Hensel have extensive experience in managing projects for CROs and Pharma/Biotech companies and we are proud to be associated with Stubbs and Hensel Consulting.  Their expertise adds to the value we bring potential partners.”

Add to Outlook Calendar

May 11 2011
Latin America
CHP has recently formed an alliance to assist companies interested in Business Development in Latin American markets.  Contact us today for a free and confidential consultation.
Add to Outlook Calendar

May 6 2011
New listings just out
Additionally, CHP has a number of clients wishing to in license late stage and marketed products in women’s health, urology, primary care, and oncology in the U.S. and  Canadian markets.
Add to Outlook Calendar

May 3 2011
Product Update
Commercial Healthcare Partners (CHP) is currently seeking partnerships for organizations wishing to in license technologies for the treatment of Crohn’s disease, oncology, pain management, and wound care.  Contact us today for a free and confidential consultation.
Add to Outlook Calendar

© 2020 by Commercial Healthcare Partners. Website Design & Development by Birchwood Group   Commercial Healthcare Partners    Jim Usry